Akèy › Skleroz an milti pwogresif kwonik › Arizona
Etid klinik pou Skleroz an milti pwogresif kwonik nan Arizona
4 etid pou Skleroz an milti pwogresif kwonik ap chèche patisipan nan sit nan Arizona.
Vil nan Arizona
Tèks ofisyèl etid la (Anglè)
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
- Clinical Endpoints, LLC, Scottsdale
Ap rekriteFaz 4
Laj 18 a 65 · Tout sèks · Mizajou Sep 30, 2026 · NCT07609719A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Arizona Neuroscience Research, LLC, Phoenix
- Perseverance Research Center, LLC (PRC), Scottsdale
Ap rekriteFaz 3
Laj 18 a 60 · Tout sèks · Mizajou Sep 30, 2026 · NCT07299019A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Arizona Neuroscience Research, LLC, Pheonix
- Perseverance Research Center, Scottsdale
Ap rekriteFaz 3
Laj 18 a 60 · Tout sèks · Mizajou Sep 22, 2026 · NCT07067463A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Ctr for Neurology and Spine, Phoenix
- AZ Integrated Neuro and Spine, Phoenix
- Center for Neurosciences, Tucson
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Jul 29, 2026 · NCT07225504Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.